Tilray (TLRY) appoints former Goldman Sachs Managing Director to Chief Corporate Development Officer

: TLRY | Tilray, Inc. - Class 2 Common Stock News, Ratings, and Charts

TLRY – In his new role, Pucher will be responsible for Tilray’s corporate development and will also manage the team responsible for M&A and corporate investments.


Tilray Inc. TLRY 0.52% on Wednesday announced the expansion of its global senior leadership team. The company appointed Andrew Pucher, a former managing director atGoldman Sachs Group Inc GS 0.15%, as its new Chief Corporate Development Officer.

In his new role, Pucher will be responsible for Tilray’s corporate development and will also manage the team responsible for M&A and corporate investments.

Pucher served as Head of Canadian Diversified Investment Banking at Goldman, where he also covered the country’s cannabis industry. Prior to that, he was a member of Goldman’s Global Healthcare Investment Banking Group, where he advised on over $200 billion in announced M&A and financing transactions, mostly in the biopharmaceutical industry.

Why It’s Important

The appointment follows a string of hires from other industries:

  • In January, Greg Christopher joined Tilray from Nestle as EVP of Operations;
  • Rita Seguin from Diageo became Tilray’s EVP of Human Resources;
  • General Counsel Dara Redler previously worked at Coca-Cola; and
  • Charlie Cain, formerly of Starbucks, was appointed VP of Retail.

The appointment comes after Tilray signed a number of deals and partnerships expanding its reach and international presence.

The company and its subsidiaries formed a partnership with Novartis AG NVS 0.64%‘s Sandoz division to distribute medical products, created a 50/50 joint venture with Anheuser Busch Inbev NV BUD 1.2%‘s Labatt to develop THC and CBD-infused beverages, signed an agreement to produce CBD products for Authentic Brands Group. Most recently, Tilray announced the acquisition of Manitoba Harvest, the largest manufacturer of hemp food products.


Tilray Inc. shares were trading at $72.09 per share on Thursday afternoon, up $0.29 (+0.40%). Year-to-date, TLRY has gained 2.20%, versus a 12.49% rise in the benchmark S&P 500 index during the same period.

TLRY currently has a StockNews.com POWR Rating of NR (Not Rated), and is ranked # of 201 stocks in the Medical – Pharmaceuticals category.


This article is brought to you courtesy of Benzinga.

TLRY at a Glance

TLRY Current POWR Rating™
Overall POWR Rating™
TLRY Current Price $67.16 4.40%
More TLRY Ratings, Data, and News

TLRY Price Reaction

The day of this event (Mar. 14, 2019)
TLRY Closing Price$72.29 0.68%
TLRY Volume1,202,400
75.87% from avg
Leading up to this event
TLRY 1-mo return6.29%
After this event
TLRY 1-day return0.97%
TLRY 3-day return2.88%
TLRY 5-day return2.21%

TLRY Price Chart



More Tilray, Inc. - Class 2 Common Stock (TLRY) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All TLRY News
Page generated in 0.4967 seconds.